Background: We aimed to update the 2010 evidence- and consensus-based national clinical guideline on the diagnosis and management of uncomplicated urinary tract infections (UTIs) in adult patients. Results are published in 2 parts. Part 1 covers methods, the definition of patient groups, and diagnostics. This second publication focuses on treatment of acute episodes of cystitis and pyelonephritis as well as on prophylaxis of recurrent UTIs. Materials and Methods: An interdisciplinary group consisting of 17 representatives of 12 medical societies and a patient representative was formed. Systematic literature searches were conducted in MEDLINE, EMBASE, and the Cochrane Library to identify literature published in 2010–2015. Results: For the treatment of acute uncomplicated cystitis (AUC), fosfomycin-trometamol, nitrofurantoin, nitroxoline, pivmecillinam, and trimethoprim (depending on the local rate of resistance) are all equally recommended. Cotrimoxazole, fluoroquinolones, and cephalosporins are not recommended as antibiotics of first choice, for concern of an unfavorable impact on the microbiome. Mild to moderate uncomplicated pyelonephritis should be treated with oral cefpodoxime, ceftibuten, ciprofloxacin, or levofloxacin. For AUC with mild to moderate symptoms, instead of antibiotics symptomatic treatment alone may be considered depending on patient preference after discussing adverse events and outcomes. Primarily non-antibiotic options are recommended for prophylaxis of recurrent urinary tract infection. Conclusion: In accordance with the global antibiotic stewardship initiative and considering new insights in scientific research, we updated our German clinical UTI guideline to promote a responsible antibiotic use and to give clear hands-on recommendations for the diagnosis and management of UTIs in adults in Germany for healthcare providers and patients.

Keywords:
Urinary tract infection, Cystitis, Pyelonephritis, Therapy, Systematic review, Clinical guideline
1.
Bundesamt für Verbraucherschutz und Lebensmittelsicherheit, Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. GERMAP 2015 – Bericht über den Antibiotikaverbrauch und die Verbreitung von Antibiotikaresistenzen in der Human- und Veterinärmedizin in Deutschland. Antiinfectives Intelligence, Rheinbach, 2016.
2.
Cai T, Verze P, Brugnolli A, Tiscione D, Lucianni LG, Eccher C, Lanzafame P, Malossini G, Wagenlehner FM, Mirone V, Bjerklund Johansen TE, Pickard R, Bartoletti R: Adherence to European association of urology guidelines on prophylactic antibiotics: an important step in antimicrobial stewardship. Eur Urol 2016; 69: 276–283.
3.
Wagenlehner FM, Bartoletti R, Cek M, Grabe M, Kahlmeter G, Pickard R, Bjerklund Johansen TE: Antibiotic stewardship: a call for action by the urologic community. Eur Urol 2013; 64: 358–360.
4.
Zhou Y, Ma LY, Zhao X, Tian SH, Sun LY, Cui YM: Impact of pharmacist intervention on antibiotic use and prophylactic use in urology clean operations. J Clin PharmTher 2015; 40: 404–408.
5.
German Association of the Scientific Medical Societies (AWMF) – Standing Guidelines Commission. AWMF Guidance Manual and Rules for Guideline Development, (ed 1). 2012. http://www.awmf.org/leitlinien/awmf-regelwerk.html (accessed July 30, 2017).
6.
Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner FM: The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients: Part I. Urol Int 2018, Epub ahead of print.
7.
Kranz J, Schmidt S, Lebert C, Schneidewind L, Vahlensieck W, Sester U, Fünfstück R, Helbig S, Hofmann W, Hummers E, Kunze M, Kniehl E, Naber K, Mandraka F, Mündner-Hensen B, Schmiemann G, Wagenlehner FM: [Epidemiology, diagnostics, therapy, prevention and management of uncomplicated bacterial outpatient acquired urinary tract infections in adult patients: update 2017 of the interdisciplinary AWMF S3 guideline]. Urologe 2017; 56: 746–758.
8.
CEBM: Centre for evidence based Medicine. Levels of Evidence. http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/ (accessed march 20, 2017).
9.
Ferry SA, Holm SE, Stenlund H, Monson TJ: The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand J Infect Dis 2004; 36: 296–301.
10.
Christiaens TC, de Meyere M, Verschraegen G, Peersman W, Heytens S, de Maeseneer JM: Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract 2002; 52: 729–734.
11.
Gágyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier E: Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 2015; 351: h6544.
12.
Kronenberg A, Bütikofer L, Odutayo A, Mühlemann K, da Costa BR, Battaglia M, Meli DN, Frey P, Limacher A, Reichenbach S, Jüni P: Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ 2017; 359:j4784.
13.
Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM: Infectious diseases society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005; 40: 643–654.
14.
Kazemier BM, Koningstein FN, Schneeberger C, et al: Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial. Lancet Infect Dis 2015; 15: 1324–1333.
15.
S3-Leitlinie Strategien zur Sicherung rationale Antibiotika-Anwendung im Krankenhaus AWMF-Registernummer 092/001. www.awmf.org/leitlinien/detail/ll/092-001.html (accessed October 7, 2017).
16.
Frei U, Schober-Hasltenberg: Nierenersatztherapie in Deutschland. Bericht über Dialysebehandlung und Nierentransplantation in Deutschland 2006/2007. www.bundesverband-niere.de/fileadmin/user_upload/QuaSi-Niere-Bericht_2006-2007.pdf (accessed October 7, 2017).
17.
Grabe M, Bartoletti R, Bjerklund Johansen TE, et al: Guidelines on Urological Infections. EAU Guidelines 2015. www.uroweb.org/wpcontent/uploads/19-Urological-infections_LR2.pdf (accessed October 7, 2017).
18.
Lumsden L, Hyner GC: Effects of an educational intervention on the rate of recurrent urinary tract infection. Women Health 1985; 10: 79–86.
19.
Su SB, Wang JN, Lu CW, Guo HR: Reducing urinary tract infections among female clean room workers. J Womens Health 2006; 15: 870–876.
20.
Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G: Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol 2013; 190: 1981–1989.
21.
Albrecht U, Goos KH, Schneider B: A randomised, double-blind, placebo-controlled trial of a herbal medicinal product containing tropaeoli majoris herba (nasturtium) and armoraciae rusticanae radix (horseradish) for the prophylactic treatment of patients with chronically recurrent lower urinary tract infections. Curr Med Res Opin 2007; 23: 2415–2422.
22.
Kranjcec B, Papes D, Altarac S: D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol 2014; 32: 79–84.
23.
Larsson B, Jonasson A, Fianu S: Prophylactic effect of UVA-E in women with recurrent cystitis: a preliminary report. Curr Ther Res 1993; 53: 441–443.
24.
Melekos MD, Asbach H, Gerharz E, Zarakovitis I, Weingärtner K, Naber K: Postintercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. J Urol 1997; 101: 935–939.
25.
Pfau A, Sacks TG: Effective postcoital prophylaxis of recurrent urinary tract infections in premenopausal women: a review. Int Urogynecol J 1991; 2: 156–160.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.